Back to top
more

Health Catalyst (HCAT)

(Delayed Data from NSDQ)

$7.70 USD

7.70
388,823

-0.07 (-0.90%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $7.64 -0.06 (-0.78%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (62 out of 251)

Industry: Medical Info Systems

Better trading starts here.

Zacks News

Brian Bolan headshot

Bull Of The Day: Heath Catalyst (HCAT)

This stock had been reporting losses but posted a break-even quarter in the more recent print and that could start a new trend.

Cerner's (CERN) Latest Offering to Improve RCM Portfolio

Cerner's (CERN) latest offering is likely to streamline and automate revenue cycle via interoperability and enhanced usability.

Health Catalyst (HCAT) Reports Break-Even Earnings for Q2

Health Catalyst (HCAT) delivered earnings and revenue surprises of 100.00% and 5.20%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Health Catalyst (HCAT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Health Catalyst (HCAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

New Strong Sell Stocks for July 21st

CNO, CLOV, DMAC, HCAT and IMAX have been added to the Zacks Rank #5 (Strong Sell) List on July 21, 2021.

Health Catalyst (HCAT) Reports Q1 Loss, Tops Revenue Estimates

Health Catalyst (HCAT) delivered earnings and revenue surprises of 53.85% and 3.25%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Health Catalyst (HCAT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Health Catalyst (HCAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Health Catalyst (HCAT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Health Catalyst (HCAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Health Catalyst (HCAT) Catches Eye: Stock Jumps 5.1%

Health Catalyst (HCAT) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Health Catalyst (HCAT) Reports Q3 Loss, Tops Revenue Estimates

Health Catalyst (HCAT) delivered earnings and revenue surprises of 22.22% and 5.69%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Will Health Catalyst (HCAT) Report Negative Earnings Next Week? What You Should Know

Health Catalyst (HCAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Schrodinger (SDGR) Catches Eye: Stock Jumps 9.3%

Schrodinger (SDGR) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

1Life Healthcare (ONEM) Soars: Stock Adds 9% in Session

1Life Healthcare (ONEM) saw a big move last session, as its shares jumped 9% on the day, amid huge volumes.

Health Catalyst (HCAT) Reports Q2 Loss, Tops Revenue Estimates

Health Catalyst (HCAT) delivered earnings and revenue surprises of 37.50% and 3.24%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Why Earnings Season Could Be Great for Health Catalyst (HCAT)?

Health Catalyst (HCAT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

iRhythm (IRTC) Looks Good: Stock Adds 9.6% in Session

iRhythm (IRTC) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.

Health Catalyst (HCAT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Health Catalyst (HCAT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Urmimala Biswas headshot

3 Medical Product Stocks Set to Beat This Earnings Season

Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.

Health Catalyst's Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Health Catalyst.

Urmimala Biswas headshot

Medical Info Systems Outlook Bright Amid Coronavirus Crisis

Despite the coronavirus-led worldwide sales disruption, Medical Info Systems is one of the few sectors witnessing industry-wide growth.

The Zacks Analyst Blog Highlights: LOGI, GO, GFL, HCAT and VIE

The Zacks Analyst Blog Highlights: LOGI, GO, GFL, HCAT and VIE

Silver Standard (SSRM) to Post Q1 Earnings: What's in Store?

Silver Standard's (SSRM) first-quarter results are likely to reflect higher units of gold sold and increasing gold prices.

Should You Buy Health Catalyst (HCAT) Ahead of Earnings?

Health Catalyst (HCAT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Nalak Das headshot

6 Top Stocks to Buy Ahead of Earnings Results This Week

Despite the negative earnings trend, a handful of stocks with a favorable Zacks Rank are poised to beat earnings estimates this week.

What's in Store for GW Pharmaceuticals (GWPH) in Q1 Earnings?

GW Pharmaceuticals (GWPH) might have registered slower international sales growth from procedural deferrals due to coronavirus pandemic in Q1.